摘要
动脉粥样硬化在糖尿病人群中的发生率显著增高,其发生发展与多种因素有关,包括糖尿病本身的高血糖以及糖尿病合并症(高血压、高血脂、肥胖等)。而胰高血糖素样肽1(GLP-1)受体激动剂(GLP-1RA)是GLP-1同源类似物,具有与GLP-1相同的生理效应,可与分布在各个器官组织中的GLP-1受体结合参与多种生物调节,平稳降糖,改善胰岛功能。GLP-1RA还可通过改善血管内皮功能直接抵抗糖尿病动脉粥样硬化,同时通过间接控制糖尿病动脉粥样硬化发生的高危因素延缓其发展。因此,GLP-1RA有望成为新一代抗动脉粥样硬化药物。
The incidence of atherosclerosis in the diabetic population is significantly increased,and its occurrence and development are related to a variety of factors,including hyperglycemia of diabetes itself and diabetic complications( such as hypertension,hyperlipidemia,and obesity). Glucagon-like peptide 1( GLP-1) receptor agonist( GLP-1 RA) is a GLP-1 homologous analog,which has the same physiological effects as GLP-1,and participates in various biological regulations after binding to the GLP-1 receptor distributed in various organ tissues. It can lower blood sugar smoothly and improve islet function. GLP-1 RA can also directly resist diabetic atherosclerosis by improving vascular endothelial function,and delay the development by indirectly controlling the risk factors of diabetic atherosclerosis. Therefore,GLP-1 RA is expected to become a new generation of anti-atherosclerotic drugs.
作者
何维
王颖
HE Wei;WANG Ying(Medical College of Yangzhou University,Yangzhou 225000,China;Department of Endocrinology,Affiliated Hospital of Yangzhou University,Yangzhou 225000,China)
出处
《医学综述》
2019年第20期4069-4073,4079,共6页
Medical Recapitulate
基金
国家自然科学基金(81200596)
江苏省第五期“333工程”培养资金资助项目
扬州大学科技创新培育基金项目(2017CXJ124)
江苏省卫生计生委科研课题(Z2017018)
